Akari Therapeutics Plc Share Price

NASDAQ: AKTX

Small Cap

$0.80

+0.04

(+5.95%)

as on September 18, 2025 at 1:29 am IST

$₹

Akari Therapeutics Plc Stock Performance

as on September 18, 2025 at 1:29 am IST

Day's Low
Day's High
$0.68
Day's Price Range
$0.83
$0.8
15.00%
Downside
3.75%
Upside
52 Week's Low
52 Week's High
$0.57
52-Week Price Range
$3.85
$0.8
28.57%
Downside
381.25%
Upside

Akari Therapeutics Plc share price movements today

Previous Close: $0.76
Open: $0.72
Volume: 1.0M
Day's Low - High: $0.68 - $0.83
52 Week Low - High: $0.57 - $3.85

Akari Therapeutics Plc Historical Returns

1 Month Return: -25.24 %
3 Month Return: -36.02 %
1 Year Return: -77.26 %
3 Year Return: -94.46 %
5 Year Return: -97.9 %

Akari Therapeutics Plc Stock Fundamentals & Key Indicators

Check Akari Therapeutics Plc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$25.7M

EPS (TTM)

-0.45

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

EBITDA

-12.8M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-112.02%

Akari Therapeutics Plc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Akari Therapeutics Plc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Akari Therapeutics Plc	BUY	$25.7M	-97.9%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	252.04%	-505.15	-12.96%
Beone Medicines Ltd	NA	$39.0B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$100.3B	44.17%	27.85	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.6B	1.78%	14.1	31.37%

Stock Returns calculator for Akari Therapeutics Plc Stock including INR - Dollar returns

The Akari Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Akari Therapeutics Plc investment value today

Current value as on today

₹28,695

Returns

₹71,305

(-71.31%)

Returns from Akari Therapeutics Plc Stock

₹75,904 (-75.9%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on Akari Therapeutics Plc Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Akari Therapeutics Plc. Average target price of $4.53

Akari Therapeutics Plc Share Price Target

Get share price movements and forecasts by analysts on Akari Therapeutics Plc.

What analysts predicted

82.34%UPSIDE

Target Price

$4.53

Current Price

$0.8

Analyzed by

7 Analysts

Target

$4.53

Akari Therapeutics Plc target price $4.53, a slight upside of 82.34% compared to current price of $0.8. According to 7 analysts rating.

Akari Therapeutics Plc Stock's Interest Amongst Investors

Search interest for Akari Therapeutics Plc Stock has increased by 157% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:157% versus previous 30 day period

Akari Therapeutics Plc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-	0	-
Gross Profit	0	-	-	-	0	-	-	-	0	-
Operating Income	-4	-9	-3	-3	-5	-7	-2	-4	-3	-3
EBITDA	-4	-3	-3	-3	-5	-7	-4	-	-3	-1
Interest Expense	-	-	-	-	-	0	0	0	0	0
Depreciation	0	0	0	0	0	-	-	0	-	-
Income Before Tax	1	-2	-3	-3	-5	-7	-2	-3	-3	-1
Income Tax Expense	-	-	-	-	0	-	-	-	-	-
Net Income	1	-2	-3	-3	-5	-7	-2	-3	-3	-1
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14251.10%	0.00%

Akari Therapeutics Plc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	-	0	0	0	0	0	0	0
Operating Income	-30	-27	-34	-19	-24	-17	-17	-23	-16	-21
EBITDA	-19	-27	-37	-16	-24	-20	-17	-23	-16	-21
Interest Expense	3	9	2	0	0	0	0	5	-	0
Depreciation	-	-	0	0	0	0	0	0	0	0
Income Before Tax	-45	-18	-32	-23	-24	-20	-17	-17	-10	-19
Income Tax Expense	3	0	-4	-3	-2	-2	0	-10	-	-
Net Income	-45	-18	-27	-19	-21	-17	-17	-6	-10	-19
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Akari Therapeutics Plc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-2	0	0	-5	-7	-2	-3	-3	-1
Operating Cash Flow	-9	0	0	-4	-4	-1	-2	-2	-3
Investing Cash Flow	-	-	-	-	-	-	-	0	-
Financing Cash Flow	3	0	0	1	7	0	2	2	3
Change in Cash	7	-1	-1	1	2	-1	0	0	0

Akari Therapeutics Plc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-18	-35	-23	-24	-20	-17	-17	-10	-19
Operating Cash Flow	-24	-31	-22	-12	-16	-18	-21	-16	-12
Investing Cash Flow	-10	9	9	-	-	-	-	-	0
Financing Cash Flow	15	15	0	11	25	14	25	7	10
Change in Cash	-34	-5	-22	0	8	-4	3	-9	-1

Global Institutional Holdings in Akari Therapeutics Plc

Funds	Holdings
Palo Alto Investors, LLC	0.45%
Omnia Family Wealth, LLC	0.19%
HPM Partners LLC	0.07%
Cresset Asset Management, LLC	0.06%
Renaissance Technologies Corp	0.06%

See all

Insights on Akari Therapeutics Plc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.9% return, outperforming this stock by 144.9%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 211.0%
NEGATIVE IMPACT
Price Dip
In the last 1 month, AKTX stock has moved down by -24.5%

About Akari Therapeutics Plc

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Organisation	Akari Therapeutics Plc
Headquarters	22 Boston Wharf Road, Boston, MA, United States, 02210
Industry	Health Technology
CEO	Mr. Abizer Gaslightwala
E-voting on shares	Click here to vote

Key Management of Akari Therapeutics Plc

Name	Title
Dr. Torsten Hombeck Ph.D.	Chief Financial Officer
Dr. Satyajit Mitra Ph.D.	Executive Director & Head of Oncology
Mr. Mark F. Kubik M.B.A.	Head of Business Development - Oncology
Mr. Abizer Gaslightwala	CEO, President & Director

FAQs

What is Akari Therapeutics Plc share price today?

Akari Therapeutics Plc share price today is $0.8 as on September 18, 2025 at 1:29 am IST at the close of the market. Akari Therapeutics Plc share today touched a day high of $0.83 and a low of $0.68.

What is the 52 week high and 52 week low for Akari Therapeutics Plc share?

Akari Therapeutics Plc share touched a 52 week high of $3.85 on September 26, 2024 and a 52 week low of $0.57 on September 2, 2025. Akari Therapeutics Plc stock price today i.e. September 18, 2025 at 1:29 am IST is closed at $0.8,which is 79.22% down from its 52 week high and 40.01% up from its 52 week low.

What is Akari Therapeutics Plc's market capitalisation today?

Akari Therapeutics Plc market capitalisation is $0.00T as on September 18, 2025 at 1:29 am IST.

How to invest in Akari Therapeutics Plc Stock (AKTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Akari Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Akari Therapeutics Plc Shares that will get you 1.8750 shares as per Akari Therapeutics Plc share price of $0.8 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Akari Therapeutics Plc Stock (AKTX) from India?

Indian investors can start investing in Akari Therapeutics Plc (AKTX) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 11:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Akari Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 11:38 am IST). Based on Akari Therapeutics Plc share’s latest price of $0.8 as on September 18, 2025 at 1:29 am IST, you will get 12.5000 shares of Akari Therapeutics Plc. Learn more about fractional shares .

What are the returns that Akari Therapeutics Plc has given to Indian investors in the last 5 years?

Akari Therapeutics Plc stock has given -97.9% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?